Common Skin Cancer, Like Christie Brinkley’s, Can Often Be Cured Without Surgery
14 mars 2024 17h42 HE
|
SkinCure Oncology LLC
Christie Brinkley was diagnosed with common skin cancer and her doctor “stitched me up to perfection,” but most such cancers can be cured without surgery.
Actinic Keratosis Treatment Market Size is projected to reach USD 9.22 billion by 2031, growing at a CAGR of 4.1%: Straits Research
14 mars 2024 10h15 HE
|
Straits Research Private Limited
New York, United States, March 14, 2024 (GLOBE NEWSWIRE) -- The purpose of treating actinic keratosis, a skin condition induced by prolonged sun exposure, is to prevent these precancerous lesions...
Vidac Pharma secures approval for next phase of clinical study of lead asset in Cutaneous T-Cell Lymphoma
12 mars 2024 02h30 HE
|
Vidac Pharma Holding PLC
London (UK), March 12, 2024 (07:30 CET) – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company pioneering a...
SkinCure Oncology Unveils New Skin Cancer Treatment Technology at American Academy of Dermatology Annual Meeting in San Diego March 8-12 Booth 3555
07 mars 2024 16h35 HE
|
SkinCure Oncology LLC
BURR RIDGE, Ill., March 07, 2024 (GLOBE NEWSWIRE) -- SkinCure Oncology, the world leader in providing a comprehensive model for the delivery of Image-Guided Superficial Radiation Therapy...
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
03 janv. 2024 07h00 HE
|
Immunocore Holdings Limited
Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference (OXFORDSHIRE, England & CONSHOHOCKEN, Penn. & ROCKVILLE, Md., US, 03 January, 2024) Immunocore Holdings plc...
Vidac Pharma va mener une étude de phase 2b du VDA-1102, son candidat médicament pour le traitement de la kératose actinique en collaboration avec CentroDerm
19 déc. 2023 01h00 HE
|
Vidac Pharma Holding PLC
Londres (Royaume-Uni), 19 décembre 2023 – Vidac Pharma Holding Plc (Hambourg et Stuttgart : T9G ; ISIN : GB00BM9XQ619 ; WKN : A3DTUQ), société biopharmaceutique d'oncologie de stade clinique, a...
Vidac Pharma to conduct Phase 2b study for actinic keratosis therapeutic candidate VDA-1102 with CentroDerm
19 déc. 2023 01h00 HE
|
Vidac Pharma Holding PLC
London (UK), December 19, 2023 – Vidac Pharma Holdings Plc. (Hamburg and Stuttgart: T9G; ISIN:GB00BM9XQ619; WKN: A3DTUQ), a clinical-stage oncology biopharmaceutical company, has completed...
Derm-Biome Pharmaceuticals Announces Collaboration with Massachusetts General Hospital in Skin Cancer Study
28 nov. 2023 10h00 HE
|
Derm-Biome Pharmaceuticals, Inc
VANCOUVER, British Columbia, Nov. 28, 2023 (GLOBE NEWSWIRE) -- Derm-Biome Pharmaceuticals Inc, a Vancouver based biopharmaceutical company with a focus on skin disease, is excited to announce that...
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update
07 nov. 2023 07h00 HE
|
Immunocore Holdings Limited
Immunocore Reports Third Quarter 2023 Financial Results and Provides Business Update KIMMTRAK net revenues of £49.7 million ($60.7 million) in Q3 2023, maintaining strong momentum in major...
Skin Cancer Treatment Market to Surpass USD 18.06 Billion by 2030 Driven by Rising Incidence of Skin Cancer and Globalization of Healthcare | Research by SNS Insider
16 oct. 2023 09h05 HE
|
SNS Insider pvt ltd
Pune, Oct. 16, 2023 (GLOBE NEWSWIRE) -- “The Skin Cancer Treatment Market, as per the SNS Insider report, achieved a value of USD 9.98 Billion and is projected to attain USD 18.06 Billion by 2030,...